November 17, 2026
On November 17, the FDA approved neladalkib, a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously received the following therapy in the unresectable locally advanced or metastatic setting: One prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.
For more information, read the FDA announcement.
November 16, 2026
On November 16, the FDA approved giredestrant, an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
For more information, read the FDA announcement.
November 13, 2026
On November 13, the FDA approved durvalumab in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for or who have refused cisplatin-based chemotherapy.
For more information, read the FDA announcement and AstraZeneca press release.
November 13, 2026
On November 12, the American Cancer Society issued an updated guideline for prostate cancer screening.
For more information, read the official guideline.
November 13, 2026
On November 4, the Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Physician Fee Schedule, advancing payment policies under Medicare Part B.
For more information, read the CMS Announcement and Fact Sheet.
November 13, 2026
On November 4, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that updates Medicare payment policies and rates for hospital outpatient and Ambulatory Surgical Center (ASC) services under the Hospital Outpatient Prospective Payment System and ASC Payment System for calendar year 2027.
For more information, read the CMS Announcement and Fact Sheet.
November 10, 2026
On November 10, the FDA approved pimicotinib for adults with symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity.
For more information, read the FDA announcement.
November 6, 2026
On November 5, the FDA approved amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Amivantamab and hyaluronidase-lpuj is not indicated for patients with oropharyngeal squamous cell carcinoma that is HPV-associated.
For more information, read the FDA announcement and the Johnson & Johnson press release.
October 26, 2026
On October 26, the FDA approved talazoparib in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test.
For more information, read the FDA announcement and the Pfizer press release.
October 23, 2026
On October 16, the FDA approved pembrolizumab or pembrolizumab in combination with berahyaluronidase alfa-pmph for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
For more information, read the FDA announcement.
October 19, 2026
On October 19, the FDA approved dostarlimab for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient, as determined by an FDA-authorized test for solid tumors.
For more information, read the FDA announcement and the GSK press release.
October 14, 2026
On October 14, the FDA approved nogapendekin alfa inbakicept-pmln in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors to include patients with high-grade papillary-only tumors.
For more information, read the FDA announcement.
October 13, 2026
On September 14, the FDA approved a label update for tarlatamab-dlle for the treatment of adult patients with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. This approval means that patients receiving tarlatamab-dlle should now be monitored for six to eight hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours.
For more information, read the Amgen press release.
October 8, 2026
On October 8, the FDA approved atezolizumab in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
For more information, read the FDA announcement and the Genentech press release.
October 8, 2026
On October 7, the FDA approved tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
For more information, read the FDA announcement and the Pfizer press release.
October 8, 2026
On October 2, the FDA approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
For more information, read the FDA announcement and the Eli Lilly press release.
September 30, 2026
On September 30, Celcuity announced that gedatolisib is now commercially available in the United States for eligible patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
For more information, read the Celcuity press release.
September 25, 2026
On September 24, the FDA approved belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
For more information, read the FDA announcement and the Eisai press release.
September 25, 2026
On September 23, the FDA approved lirafugratinib, a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement.
For more information, read the FDA announcement and the Elevar Therapeutics press release.
September 18, 2026
On September 18, the FDA granted full approval to imlunestrant, an oral estrogen receptor antagonist, in combination with abemaciclib, a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
For more information, read the Eli Lilly press release.
September 11, 2026
On September 9, the FDA granted accelerated approval to sevabertinib, a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
For more information, read the FDA announcement and the Bayer press release.
September 8, 2026
On September 4, the FDA granted accelerated approval to camizestrant, an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
For more information, read the FDA announcement and the AstraZeneca press release.
August 28, 2026
On August 26, the FDA approved daraxonrasib, an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
For more information, read the FDA announcement and the Revolution Medicines press release.
August 28, 2026
On August 25, the FDA approved zanidatamab-hrii:
in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and
in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.
The FDA also approved two companion diagnostic devices, the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody and the VENTANA HER2 Dual ISH DNA Probe Cocktail, for identifying patients with HER2-positive (IHC3+ or IHC2+/ISH+) gastric, gastroesophageal junction, and esophageal adenocarcinoma for treatment with Ziihera, consistent with the approved drug labeling.
For more information, read the FDA announcement and the Jazz Pharmaceuticals press release.